Outcomes of Transurethral Surgery Post-Implantable Penile Prosthesis: An Ultrasound Study

Inflatable penile prosthesis (IPP) has become a widely accepted solution for restoring erectile function, boasting high patient satisfaction rates. However, patients with IPP may also face complications such as urethral stricture, benign prostatic hyperplasia (BPH), or bladder tumors, necessitating subsequent transurethral surgeries (TUS). This study aimed to evaluate the postoperative outcomes of patients who underwent TUS following IPP placement, focusing on the challenges posed by existing conditions. After obtaining Institutional Review Board approval, the medical records of patients who underwent various TUS procedures—including Greenlight laser enucleation of the prostate, Rezum vaporization, and transurethral bladder tumor resection—were analyzed from 2014 to 2023. Patients who had their IPP implanted prior to these surgeries were included, while those who had TUS before IPP placement were excluded. Key parameters assessed included the International Prostate Symptom Score (IPSS), post-void residual (PVR) volume, prostate-specific antigen (PSA) levels, and transrectal ultrasound evaluations. Among the eight patients analyzed, fourteen TUS procedures were performed. The results showed improvements in PVR and PSA levels post-surgery, with no reported cases of infections or malfunctions of the IPP during an average follow-up of 40.5 months. Although the study was limited by a small sample size, the findings suggest that TUS can effectively address coexisting urological conditions without compromising the integrity or functionality of the IPP. Further research with larger cohorts is recommended to enhance understanding and validation of these outcomes in clinical practice.